Similar Articles |
|
Pharmaceutical Executive August 1, 2011 William Looney |
Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation. |
Pharmaceutical Executive July 1, 2012 William Looney |
The Learning Curve In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises; change for pharma is here and it's good. |
Pharmaceutical Executive June 1, 2013 Tom Reynolds |
Finding Strategic Levers in the Supply Chain Customer-focused supply-chain capabilities are becoming a more important part of a company's competitive advantage. |
Pharmaceutical Executive April 1, 2012 |
Leading from the South India's most prominent scientist sets a new agenda for pharma in emerging markets. |
Pharmaceutical Executive July 1, 2009 |
Swallowing the Innovator's Rx Capitalize on the new age in healthcare with "disruptive innovation." |
Pharmaceutical Executive September 1, 2012 Roy F. Waldron |
Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? |
Pharmaceutical Executive August 1, 2014 Ben Comer |
Pharm Exec's 2014 Emerging Pharma Leaders This year's class of 15 young executives is deeply of the moment, with wide-ranging therapeutic, business, and operational expertise. |
Pharmaceutical Executive November 1, 2013 |
Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation. |
Pharmaceutical Executive September 1, 2005 Wolfgang Klietmann |
Thought Leader: (Eco)systemic Change The author discusses how various players within the healthcare system interact. |
Pharmaceutical Executive January 1, 2012 William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. |
Pharmaceutical Executive July 1, 2012 |
Emerging Pharma Leaders 2012 Meet 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history by doing better with less while tapping new opportunities from science and technology to build competitive scale? |
Pharmaceutical Executive April 1, 2006 Christensen, McLaughlin & Wunker |
The Road to Nowhere? More effective drugs? Another dead end. But patients open their wallets when a "good enough" drug gets better. |
Pharmaceutical Executive September 1, 2011 Richard Barker |
Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science. |
Pharmaceutical Executive June 1, 2011 |
Are You Ready for the New China? The ability to act as a good corporate citizen and assert a useful role in national industrial policy on health is going to be essential to success in the new China. |
Pharmaceutical Executive August 1, 2014 William Looney |
A Mission to Transform Mid-career students at Brown University's new Executive Masters in Healthcare Leadership program are challenging the status quo with workplace projects focused on one thing: removing the organizational silos. |
Nursing Management October 2011 Edna Cadmus |
Your role in redesigning healthcare We need to rethink how we provide care and to understand the interconnectedness and the structure of healthcare by looking at it as a whole vs. the sum of its parts. As leaders we need to view the evidence as we rethink healthcare together. |
Pharmaceutical Executive August 1, 2011 Jennifer Ringler |
The Adherence Fight: A TKO? Why does the match against medicines compliance always seem to end in an easy knockout? |
Nursing Management September 2010 Richard Hader |
The evidence that isn't... Interpreting research When patients seek a healthcare practitioner for services, they believe that the delivered care is based on proven science. But reality is far from patient perception. In fact, most care is still based on anecdote, not evidence. |
Pharmaceutical Executive October 1, 2011 |
Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy. |
Pharmaceutical Executive April 1, 2014 William Looney |
The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines. |
Pharmaceutical Executive March 1, 2011 William Looney |
John Castellani: Industry's Level Bet on a Dizzying Future Can PhRMA's own business model sync with industry's Pharm Exec takes a closer look at PhRMA's new leadership. |
Pharmaceutical Executive August 1, 2012 |
Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency. |
Pharmaceutical Executive April 1, 2011 |
Bridging the HCP-Patient Gap Here's what's necessary to bridge the gap between the patient revolution and healthcare provider in the 21st century. |
Pharmaceutical Executive December 1, 2011 |
UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity. |
Pharmaceutical Executive February 1, 2013 William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
Pharmaceutical Executive May 1, 2012 |
Super-Size Me Finding opportunities in the information explosion: big data, big challenges and big rewards. |
Pharmaceutical Executive March 1, 2014 William Looney |
The Call to Community: A Conversation with Dr. David Nash Population health is the foundation for much of what is truly new in US health reform. For big Pharma, it represents yet another escalation in expectations. |
Pharmaceutical Executive December 1, 2010 Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Nursing Management September 2008 Richard Hader |
Strategies for profitable growth Experience has demonstrated that a focus on expense reduction alone won't sustain or improve financial stability in health care services. |
Pharmaceutical Executive September 1, 2013 Jordan Sarver |
Pathology in the Era of Personalized Medicine With their knowledge of molecular genetics, Pathologists are transforming the way healthcare is provided. |
Pharmaceutical Executive December 1, 2011 William Looney |
The Medicines Adherence Challenge Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma, but is it? An expert round table examines how best to make progress and agree on some practical steps for incorporation in the campaign agenda. |
Pharmaceutical Executive January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. |
Pharmaceutical Executive September 1, 2013 William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Pharmaceutical Executive September 1, 2012 Stan Bernard |
The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model. |
Pharmaceutical Executive June 1, 2011 |
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity? |
Pharmaceutical Executive February 1, 2012 Sarah Krug |
Introducing the 'Chief Patient Officer' Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust. |
Pharmaceutical Executive August 1, 2013 Joseph Saba |
New Rules for a New Africa Declining revenue growth in the United States and Europe have sent pharmaceutical companies in search of opportunities in the BRICs and other emerging economies. Now, companies are finally turning their attention to Africa. |
Pharmaceutical Executive September 1, 2012 Robin Hertz |
The Endless Treadmill of End-of-Life Care Bending the cost curve back to valuing the cycle of life. |
InternetNews November 14, 2006 Michael Hickins |
More Than Second Life in IBM's $100M Spend Where else is Big Blue's $100 million investment in virtual worlds going? |
InternetNews August 5, 2004 Clint Boulton |
Mayo Clinic to Use IBM's Blue Gene The clinic will use IBM's supercomputer to map current and historical patient records and link them to new types of medical information. |
IndustryWeek December 1, 2003 John Teresko |
Technology Leader Of The Year -- Interconnecting Innovation For 36 years, Nicholas M. Donofrio has helped IBM Corp. and its customers innovate toward greater value. Now responsible for IBM's technology and manufacturing, he wants to accelerate that process by making a more direct connection between R&D and customer needs. |
Pharmaceutical Executive May 1, 2012 |
Country Report: South Africa In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory. |
HBS Working Knowledge June 29, 2015 Dina Gerdeman |
Consumer-centered Health Care Depends on Accessible Medical Records John Quelch discusses approaches to integrate patient data so that medical professionals and patients can make better decisions. |
Chemistry World August 23, 2012 Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
Pharmaceutical Executive June 1, 2014 Ben Comer |
Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy. |
Pharmaceutical Executive January 21, 2014 Comer & Upton |
Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday. |
Pharmaceutical Executive December 1, 2011 William Looney |
2011: End of the Beginning The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item. |
Nursing Management April 2012 Gloria Kersey-Matusiak |
Culturally competent care: Are we there yet? What exactly is culturally competent care, and how can you use it to lessen healthcare disparities among your patients? |
HBS Working Knowledge April 5, 2004 Jonathan Byrnes |
Fixing the Healthcare Supply Chain The paradox of healthcare supply chains is that they are the home of some of the best and worst practices in supply chain management. With limited hospital budgets, supply chain inefficiencies consume resources that could be used to bring important therapies into more widespread availability. |
Pharmaceutical Executive September 1, 2005 Parker & Amar |
Building Blockbusters The most lucrative new drugs are often less glamorous than first-in-class new molecular entities. And they are much less risky. |